Orthopediatrics Corp (KIDS) - Net Assets
Based on the latest financial reports, Orthopediatrics Corp (KIDS) has net assets worth $346.60 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($523.08 Million) and total liabilities ($176.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Orthopediatrics Corp (KIDS) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $346.60 Million |
| % of Total Assets | 66.26% |
| Annual Growth Rate | 30.86% |
| 5-Year Change | 53.79% |
| 10-Year Change | 5682.38% |
| Growth Volatility | 198.4 |
Orthopediatrics Corp - Net Assets Trend (2014–2025)
This chart illustrates how Orthopediatrics Corp's net assets have evolved over time, based on quarterly financial data. Also explore Orthopediatrics Corp asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Orthopediatrics Corp (2014–2025)
The table below shows the annual net assets of Orthopediatrics Corp from 2014 to 2025. For live valuation and market cap data, see Orthopediatrics Corp (KIDS) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $346.60 Million | -2.25% |
| 2024-12-31 | $354.57 Million | -5.96% |
| 2023-12-31 | $377.02 Million | -0.43% |
| 2022-12-31 | $378.65 Million | +68.01% |
| 2021-12-31 | $225.37 Million | -4.00% |
| 2020-12-31 | $234.77 Million | +64.91% |
| 2019-12-31 | $142.36 Million | +74.18% |
| 2018-12-31 | $81.73 Million | +72.09% |
| 2017-12-31 | $47.49 Million | +692.38% |
| 2016-12-31 | $5.99 Million | -47.03% |
| 2015-12-31 | $11.31 Million | -37.06% |
| 2014-12-31 | $17.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Orthopediatrics Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21154100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Comprehensive Income | $-523.00K | -0.15% |
| Other Components | $622.33 Million | 179.55% |
| Total Equity | $346.60 Million | 100.00% |
Orthopediatrics Corp Competitors by Market Cap
The table below lists competitors of Orthopediatrics Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Meilun Elevator Co Ltd
SHG:603321
|
$395.15 Million |
|
MK Electron Co. Ltd
KQ:033160
|
$395.23 Million |
|
Schweiter Technologies AG
LSE:0QR1
|
$395.31 Million |
|
Brasilagro Adr
NYSE:LND
|
$395.47 Million |
|
Shandong Teamgene Technology Co. Ltd. A
SHG:603151
|
$395.08 Million |
|
BTQ Technologies Corp.
NEO:BTQ
|
$395.04 Million |
|
Hemisphere Properties India Limited
NSE:HEMIPROP
|
$394.89 Million |
|
Zhejiang Dayang Biotech Group Co
SHE:003017
|
$394.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orthopediatrics Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 354,566,000 to 346,596,000, a change of -7,970,000 (-2.2%).
- Net loss of 39,648,000 reduced equity.
- Other comprehensive income increased equity by 10,250,000.
- Other factors increased equity by 21,428,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.65 Million | -11.44% |
| Other Comprehensive Income | $10.25 Million | +2.96% |
| Other Changes | $21.43 Million | +6.18% |
| Total Change | $- | -2.25% |
Book Value vs Market Value Analysis
This analysis compares Orthopediatrics Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.47x to 1.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $2.42 | $15.63 | x |
| 2015-12-31 | $1.51 | $15.63 | x |
| 2016-12-31 | $0.80 | $15.63 | x |
| 2017-12-31 | $9.86 | $15.63 | x |
| 2018-12-31 | $6.50 | $15.63 | x |
| 2019-12-31 | $9.73 | $15.63 | x |
| 2020-12-31 | $13.00 | $15.63 | x |
| 2021-12-31 | $11.70 | $15.63 | x |
| 2022-12-31 | $18.08 | $15.63 | x |
| 2023-12-31 | $16.63 | $15.63 | x |
| 2024-12-31 | $15.36 | $15.63 | x |
| 2025-12-31 | $14.77 | $15.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orthopediatrics Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.78%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.51x
- Recent ROE (-11.44%) is above the historical average (-27.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -53.12% | -40.32% | 0.66x | 1.99x | $-11.35 Million |
| 2015 | -69.74% | -25.45% | 1.01x | 2.71x | $-9.02 Million |
| 2016 | -109.64% | -17.62% | 1.22x | 5.12x | $-7.17 Million |
| 2017 | -18.81% | -19.58% | 0.55x | 1.73x | $-13.68 Million |
| 2018 | -14.71% | -20.89% | 0.51x | 1.37x | $-20.20 Million |
| 2019 | -9.65% | -18.93% | 0.37x | 1.37x | $-27.97 Million |
| 2020 | -14.03% | -46.35% | 0.22x | 1.38x | $-56.42 Million |
| 2021 | -7.21% | -16.58% | 0.32x | 1.37x | $-38.80 Million |
| 2022 | 0.33% | 1.03% | 0.29x | 1.13x | $-36.61 Million |
| 2023 | -5.56% | -14.10% | 0.34x | 1.16x | $-58.68 Million |
| 2024 | -10.67% | -18.47% | 0.43x | 1.33x | $-73.28 Million |
| 2025 | -11.44% | -16.78% | 0.45x | 1.51x | $-74.31 Million |
Industry Comparison
This section compares Orthopediatrics Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,432,799,891
- Average return on equity (ROE) among peers: -74.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Orthopediatrics Corp (KIDS) | $346.60 Million | -53.12% | 0.51x | $395.11 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $21.60 Million |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Orthopediatrics Corp
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sp… Read more